GlassScriptPhysician profile
Henry K Purvis
NPI 1780687954
$9,330.80
in general payments reported to CMS, 2019-2025
46 companies · $99.93 in 2025
The $99.93 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $1,273 · 2021: $1,548 · 2022: $2,154 · 2023: $1,984 · 2024: $1,522 · 2025: $99.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,605.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,040.61 | 2019-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $990.65 | 2021-2025 | |
| Novo Nordisk INC | $835.20 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $736.30 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $541.29 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $541.18 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $536.35 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $417.32 | 2022-2023 | |
| Esperion Therapeutics, INC. | $309.67 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $261.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $237.32 | 2021-2023 | |
| Dexcom, INC. | $182.80 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $175.39 | 2020-2024 | Belsomra, Januvia, Steglatro |
| Amarin Pharma, INC. | $163.56 | 2019-2021 | |
| Atricure, INC. | $144.75 | 2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $141.51 | 2020-2024 | Austedo Xr, Airduo Digihaler |
| Glaxosmithkline, LLC. | $140.10 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $135.55 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $132.91 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $131.50 | 2019-2023 | Livalo, Seglentis |
| Axsome Therapeutics, INC. | $128.58 | 2024 | Auvelity |
| Lundbeck LLC | $126.70 | 2023-2024 | Rexulti |
| Allergan, INC. | $123.66 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $115.33 | 2022-2024 | Rexulti, Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.89 | 2022-2024 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $104.34 | 2022-2023 | Quviviq |
| Tris Pharma INC | $97.21 | 2022-2024 | Dyanavel Xr |
| Boston Scientific Corporation | $77.24 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Alkermes, INC. | $72.96 | 2023 | Lybalvi |
| Ironshore Pharmaceuticals INC. | $56.70 | 2019-2024 | Jornay Pm |
| Biohaven Pharmaceuticals, INC. | $54.05 | 2021 | |
| Eisai INC. | $50.47 | 2020-2021 | |
| Abbott Laboratories | $47.04 | 2021-2022 | |
| Harmony Biosciences LLC | $46.34 | 2023-2024 | Wakix |
| Astellas Pharma US INC | $44.23 | 2023-2024 | Veozah |
| Vbi Vaccine (Delaware) INC. | $43.21 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $37.79 | 2020-2023 | Xarelto |
| Exact Sciences Corporation | $33.51 | 2024 | Cologuard Collection Kit |
| Shire North American Group INC | $29.28 | 2019 | |
| Genentech USA, INC. | $26.61 | 2020-2021 | |
| Gilead Sciences, INC. | $26.09 | 2021 | |
| Bausch Health US, LLC | $14.48 | 2021 | |
| Sumitomo Pharma America, INC. | $12.18 | 2023 | Gemtesa |
| Upsher-Smith Laboratories LLC | $11.78 | 2020 | |
| Neuronetics, INC. | $8.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Purvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.